📊 CLDWW Key Takeaways
Investment Thesis
Calidi Biotherapeutics is a pre-revenue biotech company with severe cash burn and deteriorating financial fundamentals. With only $45K in revenue against $15.8M in operating losses and $16.2M in negative operating cash flow, the company is burning through capital at an unsustainable rate. Despite adequate liquidity currently, the operational trajectory is deeply concerning with no clear path to profitability.
CLDWW Strengths
- Current liquidity position with $10.4M in cash provides near-term runway
- Low debt burden with debt-to-equity ratio of 0.09x limits leverage risk
- Current ratio of 2.12x indicates ability to meet short-term obligations
CLDWW Risks
- Massive operating losses of $15.8M on only $45K revenue indicates negligible commercialization progress
- Free cash flow of -$16.2M annually will deplete $10.4M cash reserves within 6-8 months without capital raise
- Negative operating margin of -35,053% and negative ROE of -229% demonstrate severe value destruction
- No insider buying activity in past 90 days suggests lack of confidence from management
- Pre-revenue stage company with clinical-stage risk profile typical of failed biotech programs
Key Metrics to Watch
- Cash runway and timing of next capital requirement
- Monthly cash burn rate and ability to extend runway
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue recognition from any licensing or partnership deals
- Operating cash flow trajectory
CLDWW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
CLDWW Profitability Ratios
CLDWW vs Healthcare Sector
How Calidi Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLDWW Balance Sheet & Liquidity
CLDWW 5-Year Financial Trend
5-Year Trend Summary: Calidi Biotherapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.33 indicates the company is currently unprofitable.
CLDWW Growth Metrics (YoY)
CLDWW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $45.0K | -$2.0M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLDWW Capital Allocation
CLDWW SEC Filings
Access official SEC EDGAR filings for Calidi Biotherapeutics, Inc. (CIK: 0001855485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLDWW
What is the AI rating for CLDWW?
Calidi Biotherapeutics, Inc. (CLDWW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLDWW's key strengths?
Current liquidity position with $10.4M in cash provides near-term runway. Low debt burden with debt-to-equity ratio of 0.09x limits leverage risk.
What are the risks of investing in CLDWW?
Massive operating losses of $15.8M on only $45K revenue indicates negligible commercialization progress. Free cash flow of -$16.2M annually will deplete $10.4M cash reserves within 6-8 months without capital raise.
What is CLDWW's revenue and growth?
Calidi Biotherapeutics, Inc. reported revenue of $45.0K.
Does CLDWW pay dividends?
Calidi Biotherapeutics, Inc. does not currently pay dividends.
Where can I find CLDWW SEC filings?
Official SEC filings for Calidi Biotherapeutics, Inc. (CIK: 0001855485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLDWW's EPS?
Calidi Biotherapeutics, Inc. has a diluted EPS of $-6.40.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.